公开(公告)号：EP0693925A1

公开(公告)日：1996-01-31

申请号：EP94914102.0

申请日：1994-04-08

申请人： BIO-TECHNOLOGY GENERAL CORP. ,  YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM

发明人： WERBER, Moshe M. ,  ZEELON, Elisha P. ,  LEVANON, Avigdor ,  GUY, Rachel ,  GOLDLUST, Arie ,  RIGBI, Meir ,  PANET, Amos ,  FISCHER, Meir

IPC分类号： C12N15 ,  A61K38 ,  A61P7 ,  A61P31 ,  A61P43 ,  C07K1 ,  C07K14 ,  C07K16 ,  C12N1 ,  C12N9 ,  C12P21 ,  C12R1

CPC分类号： C07K14/815 ,  A61K38/00 ,  C07K16/38

摘要： The present invention provides a recombinant polypeptide having the amino acid sequence X-tyr?26 - gly110¿ where tyr?26 - gly110¿ is identical to the sequence shown in Figure 10, and wherein X is methionine or absent and wherein asn72 may be substituted by pro. The invention further provides a method of producing the polypeptide which comprises transforming a host cell with an expression plasmid encoding the polypeptide, culturing the transformed host cell so that the cell produces the polypeptide encoded by the plasmid, and a method of recovering the polypeptide so produced.

公开(公告)号：EP0659085A1

公开(公告)日：1995-06-28

申请号：EP93919995.0

申请日：1993-08-12

申请人： BIO-TECHNOLOGY GENERAL CORP.

发明人： VOGEL, Tikva ,  PANET, Amos

IPC分类号： A61K38 ,  A61P35 ,  A61P43 ,  C07K14

CPC分类号： C07K14/775 ,  A61K38/1709 ,  A61K2300/00

摘要： The present invention provides a use of ApoE for inhibition of proliferation of actively proliferating cells including tumor cells. This method comprises contacting the cells with an amount of Apolipoprotein E (ApoE) effective to inhibit cell proliferation.

公开(公告)号：EP0701606A1

公开(公告)日：1996-03-20

申请号：EP94915405.0

申请日：1994-04-22

申请人： BIO-TECHNOLOGY GENERAL CORP.

发明人： GARFINKEL, Leonard ,  GORECKI, Marian ,  PANET, Amos

IPC分类号： C12N15 ,  A61K31 ,  A61K38 ,  A61P7 ,  A61P9 ,  C07K14 ,  C12N9 ,  C12P21 ,  C12R1

CPC分类号： C07K14/755 ,  A61K38/37 ,  A61K38/49 ,  A61K31/60 ,  A61K2300/00

摘要： A method is provided for the use of a fragment of von Willebrand Factor (vWF) comprising the platelet glycoprotein Ib (GPIb) binding domain in conjunction with known therapies to obtain enhanced protection against thrombosis, improved thrombolysis, and a decreased likelihood of reocclusion following thrombolytic treatment. Additionally, a method is provided for the use of the vWF fragment and aspirin to prevent complications following traumatic vascular damage.